A broad Italian experience with eribulin mesylate in metastatic breast cancer patients: The ESEMPiO study

Authors :: Maria Morritti
Sandro Barni
Arianna Pellegrino
Ornella Garrone
Mario Airoldi
Mariangela Ciccarese
Caterina Fontanella
Lucia Del Mastro
Loretta D'Onofrio
Vita Leonardi
Andrea Michelotti
Luca Porcu
A. Latorre
Marco Pistelli
Laura Pizzuti
Luca Livraghi
Francesca Martella
Stefania Eufemia Lutrino
Laura Iezzi
Nicla La Verde
Source :: Journal of Clinical Oncology. 33:e11539-e11539
Publication Year :: 2015
Publisher :: American Society of Clinical Oncology (ASCO), 2015.
Abstract: e11539 Background: Eribulin Mesylate (EM) has been available in Italy since January 4th, 2012 for the treatment of patients (pts) with metastatic breast cancer (MBC) after the failure of at least 2...

Subjects :: Oncology
Eribulin Mesylate
Cancer Research
medicine.medical_specialty
business.industry
medicine.disease
Metastatic breast cancer
Surgery
Internal medicine
medicine
bacteria
skin and connective tissue diseases
business

Full Text Access

Tools